Government Buys $37 Million of a Last Resort Antibiotic as Hard to Treat Hospital Infections Persist

BARDA exercised a $36.9 million option for cefiderocol, an antibiotic reserved for drug-resistant infections and possible biothreat pathogens.

Have A Referral?